Business Context and Reporting Period
This Form 6-K filing covers the month of January 2023 for Bionomics Limited, a foreign issuer headquartered in Eastwood, South Australia. The filing serves to disclose regulatory notifications lodged with the Australian Securities Exchange (ASX) regarding changes in securities interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of corporate governance events rather than a financial performance statement.
Material Changes
The filing discloses two specific material events regarding securities interests:
- Director's Initial Interest: Notification lodged for Spyros Papapetropoulos (Appendix 3X).
- Cessation of Securities: Notification regarding the expiry of unlisted options under the Company's employee incentive plan (Appendix 3H).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the submission of ASX notifications as exhibits.
Investor Verification Checklist
- Verify the specific number of shares or options involved in Spyros Papapetropoulos' initial interest.
- Confirm the total number of unlisted options that expired under the employee incentive plan.
- Review the full text of Exhibits 99.1 and 99.2 for detailed transaction terms.